Jim Simons Supernus Pharmaceuticals, Inc. Transaction History

Renaissance Technologies LLC

$70.6 Billion
Q2 2025

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 1,655,322 shares of SUPN stock, worth $82.4 Million. This represents 0.07% of its overall portfolio holdings.

Number of Shares

1,655,322

Previous 1,585,722 4.39%

Holding current value

$82.4 Million

Previous $51.9 Million 0.47%

% of portfolio

0.07%

Previous 0.08%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 13, 2025	BUY	$30.29 - $33.43 $2.11 Million - $2.33 Million	69,600 Added 4.39%	1,655,322 $52.2 Million
Q1 2025 May 14, 2025	SELL	$31.17 - $40.0 $405,210 - $520,000	-13,000 Reduced 0.81%	1,585,722 $51.9 Million
Q4 2024 Feb 13, 2025	SELL	$31.89 - $37.83 $4.14 Million - $4.91 Million	-129,900 Reduced 7.51%	1,598,722 $57.8 Million
Q3 2024 Nov 13, 2024	BUY	$25.77 - $35.16 $1.12 Million - $1.53 Million	43,500 Added 2.58%	1,728,622 $53.9 Million
Q2 2024 Aug 09, 2024	BUY	$25.99 - $33.85 $9.15 Million - $11.9 Million	351,900 Added 26.39%	1,685,122 $45.1 Million
Q1 2024 May 13, 2024	SELL	$27.11 - $35.17 $1.23 Million - $1.59 Million	-45,200 Reduced 3.28%	1,333,222 $45.5 Million
Q4 2023 Feb 13, 2024	SELL	$22.72 - $29.68 $1.36 Million - $1.78 Million	-60,000 Reduced 4.17%	1,378,422 $39.9 Million
Q3 2023 Nov 14, 2023	SELL	$27.57 - $32.91 $1.6 Million - $1.91 Million	-57,900 Reduced 3.87%	1,438,422 $39.7 Million
Q2 2023 Aug 11, 2023	BUY	$29.91 - $38.73 $3.07 Million - $3.98 Million	102,800 Added 7.38%	1,496,322 $45 Million
Q1 2023 May 12, 2023	BUY	$34.93 - $42.03 $4.65 Million - $5.59 Million	133,000 Added 10.55%	1,393,522 $50.5 Million
Q4 2022 Feb 13, 2023	SELL	$31.09 - $37.88 $612,473 - $746,236	-19,700 Reduced 1.54%	1,260,522 $45 Million
Q3 2022 Nov 14, 2022	SELL	$28.79 - $35.41 $3.36 Million - $4.14 Million	-116,800 Reduced 8.36%	1,280,222 $43.3 Million
Q2 2022 Aug 12, 2022	BUY	$25.33 - $34.25 $3.89 Million - $5.26 Million	153,500 Added 12.34%	1,397,022 $40.4 Million
Q1 2022 May 13, 2022	BUY	$28.51 - $32.9 $125,444 - $144,760	4,400 Added 0.36%	1,243,522 $40.2 Million
Q4 2021 Feb 11, 2022	SELL	$26.37 - $34.22 $3.94 Million - $5.12 Million	-149,500 Reduced 10.77%	1,239,122 $36.1 Million
Q3 2021 Nov 12, 2021	SELL	$23.54 - $31.39 $3 Million - $4.01 Million	-127,600 Reduced 8.42%	1,388,622 $37 Million
Q2 2021 Aug 13, 2021	SELL	$26.72 - $33.19 $6.52 Million - $8.1 Million	-244,000 Reduced 13.86%	1,516,222 $46.7 Million
Q1 2021 May 13, 2021	SELL	$24.15 - $31.45 $2.16 Million - $2.81 Million	-89,300 Reduced 4.83%	1,760,222 $46.1 Million
Q4 2020 Feb 10, 2021	SELL	$17.7 - $25.81 $335,910 - $489,822	-18,978 Reduced 1.02%	1,849,522 $46.5 Million
Q3 2020 Nov 13, 2020	BUY	$20.2 - $25.05 $5.57 Million - $6.91 Million	275,700 Added 17.31%	1,868,500 $38.9 Million
Q2 2020 Aug 13, 2020	BUY	$17.09 - $24.89 $11.8 Million - $17.2 Million	690,600 Added 76.55%	1,592,800 $37.8 Million
Q1 2020 May 14, 2020	SELL	$14.45 - $24.69 $273,105 - $466,641	-18,900 Reduced 2.05%	902,200 $16.2 Million
Q4 2019 Feb 13, 2020	BUY	$19.93 - $29.13 $7.15 Million - $10.5 Million	358,900 Added 63.84%	921,100 $21.8 Million
Q3 2019 Nov 13, 2019	SELL	$25.47 - $33.37 $1.07 Million - $1.4 Million	-42,000 Reduced 6.95%	562,200 $15.4 Million
Q2 2019 Aug 12, 2019	BUY	$29.96 - $38.87 $4.25 Million - $5.52 Million	141,900 Added 30.69%	604,200 $20 Million
Q1 2019 May 14, 2019	BUY	$32.77 - $41.99 $3.89 Million - $4.99 Million	118,800 Added 34.59%	462,300 $16.2 Million
Q4 2018 Feb 13, 2019	BUY	$30.84 - $49.51 $10.6 Million - $17 Million	343,500 New	343,500 $11.4 Million

Others Institutions Holding SUPN

# of Institutions

313

Shares Held

61.5M

Call Options Held

18.4K

Put Options Held

View Full List

About SUPERNUS PHARMACEUTICALS, INC.

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $2.66B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

More about SUPN

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account